GlassScriptPhysician profile
Claire Atkinson
NPI 1255868485
$9,043.40
in general payments reported to CMS, 2019-2025
23 companies · $6,188 in 2025
The $6,188 reported for 2025 was more than what 87% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $466 · 2022: $482 · 2023: $1,110 · 2024: $798 · 2025: $6,188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,825 · Food and Beverage: $3,501 · Travel and Lodging: $612 · Education: $158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,825.00 |
| Food and Beverage | $3,500.99 |
| Travel and Lodging | $611.50 |
| Education | $158.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $4,879.40 | 2022-2025 | Xolair |
| Astrazeneca Pharmaceuticals LP | $956.28 | 2021-2025 | Tezspire, Fasenra, Airsupra |
| Genzyme Corporation | $681.12 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $631.43 | 2021-2025 | Dupixent |
| Glaxosmithkline, LLC. | $468.33 | 2023-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Csl Behring | $351.12 | 2021-2025 | Hizentra, Haegarda |
| Alk-Abello, INC | $145.17 | 2021-2024 | Pre-Pen, Alternaria Tenuis, Standardized Mite D. Farinae |
| Grifols USA, LLC | $133.64 | 2024-2025 | Xembify |
| Optinose US, INC. | $101.45 | 2022-2025 | |
| Pharming Healthcare, INC. | $101.43 | 2024-2025 | Ruconest |
| Amgen INC. | $100.89 | 2024-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $74.14 | 2023-2025 | Takhzyro, Cuvitru |
| Novartis Pharmaceuticals Corporation | $67.48 | 2025 | |
| Blueprint Medicines Corporation | $64.82 | 2023-2025 | Ayvakit |
| Ars Pharmaceuticals Operations, INC. | $60.18 | 2025 | Neffy |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $57.87 | 2022-2025 | Orladeyo |
| Genentech, INC. | $35.00 | 2024 | Xolair |
| Aimmune Therapeutics, INC. | $25.85 | 2022 | |
| Dermavant Sciences, INC. | $25.39 | 2024 | Vtama |
| Kaleo, INC. | $24.80 | 2023 | Auvi-Q |
| Sobi, INC | $22.39 | 2021 | |
| Greer Laboratories, INC. | $21.56 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claire Atkinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.